Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Antibody responses to cancer antigens identify patients with a poor prognosis among HPV-positive and HPV-negative head and neck squamous cell carcinoma patients.

Laban S, Gangkofner DS, Holzinger D, Schroeder L, Eichmüller SB, Zörnig I, Jäger D, Wichmann G, Dietz A, Broglie MA, Herold-Mende CC, Dyckhoff G, Boscolo-Rizzo P, Ezić J, Marienfeld R, Möller P, Kraus JM, Völkel G, Kestler HA, Brunner C, Schuler PJ, Wigand MC, Theodoraki MN, Doescher J, Hoffmann TK, Pawlita M, Waterboer T, Butt J.

Clin Cancer Res. 2019 Aug 23. pii: clincanres.1490.2019. doi: 10.1158/1078-0432.CCR-19-1490. [Epub ahead of print]

PMID:
31444248
2.

Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas.

Rapp C, Dettling S, Liu F, Ull AT, Warta R, Jungk C, Roesch S, Mock A, Sahm F, Schmidt M, Jungwirth G, Zweckberger K, Lamszus K, Gousias K, Kessler AF, Grabe N, Loehr M, Ketter R, Urbschat S, Senft C, Westphal M, Abdollahi A, Debus J, von Deimling A, Unterberg A, Simon M, Herold-Mende CC.

Clin Cancer Res. 2019 Jun 21. doi: 10.1158/1078-0432.CCR-19-0389. [Epub ahead of print]

PMID:
31227506
3.

Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma.

Mastrella G, Hou M, Li M, Stoecklein VM, Zdouc N, Volmar MNM, Miletic H, Reinhard S, Herold-Mende CC, Kleber S, Eisenhut K, Gargiulo G, Synowitz M, Vescovi AL, Harter PN, Penninger JM, Wagner E, Mittelbronn M, Bjerkvig R, Hambardzumyan D, Schüller U, Tonn JC, Radke J, Glass R, Kälin RE.

Cancer Res. 2019 May 1;79(9):2298-2313. doi: 10.1158/0008-5472.CAN-18-0881. Epub 2019 Feb 4.

PMID:
30718358
4.

A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.

Gobin M, Nazarov PV, Warta R, Timmer M, Reifenberger G, Felsberg J, Vallar L, Chalmers AJ, Herold-Mende CC, Goldbrunner R, Niclou SP, Van Dyck E.

Cancer Res. 2019 Mar 15;79(6):1226-1238. doi: 10.1158/0008-5472.CAN-18-2076. Epub 2019 Jan 23.

PMID:
30674534
5.

Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells.

Gaedicke S, Braun F, Prasad S, Machein M, Firat E, Hettich M, Gudihal R, Zhu X, Klingner K, Schüler J, Herold-Mende CC, Grosu AL, Behe M, Weber W, Mäcke H, Niedermann G.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):E692-701. doi: 10.1073/pnas.1314189111. Epub 2014 Jan 27.

6.

Insight into the complex regulation of CD133 in glioma.

Campos B, Herold-Mende CC.

Int J Cancer. 2011 Feb 1;128(3):501-10. doi: 10.1002/ijc.25687. Review.

7.

Stem cell marker CD133 affects clinical outcome in glioma patients.

Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC.

Clin Cancer Res. 2008 Jan 1;14(1):123-9. doi: 10.1158/1078-0432.CCR-07-0932.

8.

Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo.

Vasvari GP, Dyckhoff G, Kashfi F, Lemke B, Lohr J, Helmke BM, Schirrmacher V, Plinkert PK, Beckhove P, Herold-Mende CC.

Int J Cancer. 2007 Oct 15;121(8):1697-704.

10.

Supplemental Content

Loading ...
Support Center